Edigene, Inc., A Global, Clinical-Stage Company Focused On Translating Gene-Editing Technologies Into Transformative Genetic Medicines For Patients With Significant Unmet Medical Needs, Announced It Had Completed The Last Patient Dosing In Phase I Clinical Trial Of Et-01, Its Investigational Gene-Editing Hematopoietic Stem Cell Therapy For Transfusion Dependent ?-Thalassemia (Tdt).
